
Amgen's Weight-Loss Drug Falls Short, Stock Plummets
- Amgen's MariTide Phase-2 data showed 20% weight loss at 52 weeks, but stock dropped 13.31% pre-market.
- Rival stocks Eli Lilly and Novo Nordisk rose on Biden's proposal for expanded Medicare, Medicaid coverage for obesity drugs.
- Ret...